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Liver rejection in the era of cycJosporine-based immunosuppression is approximately 
60-70%. Approximately /5-25% of liver transplant patients will require hemodialysis 
following transplantation. TheseJacts argile for a potent, less nephrotoxic immunosup-
pressive regimen. especially during the period of vulnerability to these events. Prophy-
lactic use of OKT3 has been suggested as a means to decrease the need for hemodialysis 
while maintaining potent immunosuppression. The goal of this review is to examine 
potential benefits and pitfalls of this regimen. A lack of documentation of long-term 
patient and graft survival. the potential susceptibility to infectious complications. 
development of sensitization. and the cost musl be weighed against the decreased need 
for hemodialysis and the control of early rejection episodes. 
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OKT3 (orthoclone) is a murine monoclonal anti-
human T-cell antibody with clinically proven effi-
cacy in the reversal of acute renal and liver allograft 
rejection 0-7). While the major impact in improve-
ment in patient and graft survival appears to be in 
patients with acute cellular rejection. the early 
postoperative use of OKT3 has been shown to be of 
benefit in a subpopulation of patients after liver 
transplantation (5). This is related to decreased 
graft loss from rejection during a period in which 
cyclosporine use has been minimized because of 
renal dysfunction. Since OKT3 is capable of pre-
venting alloactivation ill vilm, its prophylactic lise 
should delay the onset of rejection. at least during 
the period of administration of the agent. 
The rationale for the prophylactic use of OKT3 in 
liver transplantation is primarily to decrease or mod-
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ulate the early cyclosporine-related renal dysfunction 
seen in many liver transplant patients and possibly to 
decrease the incidence and severity of acute rejection 
episodes. Renal dysfunction. either measured by ele-
vated serum creatinine or by the need for hemodial-
ysis. occurs relatively frequently after liver transplan-
tation. McCauley et al (8) noted an incidence of acute 
renal failure after liver transplantation with cyclospo-
rine-based immunosuppression of 15 -20%. The 
causes of renal failure following liver transplantation 
are multifactorial and include perioperative hypoten-
sion. use of nephrotoxic antibiotics. and preoperative 
heputorenal syndrome (9). The lise of cyclosporine 
was determined to be the sole cause 01 rCilul railun: in 
20% of patients with renal failure :·..)Ilowing liver 
transplantation and can certainly augment other 
causes of renal failure. 
SURVIV AL, RENAL FUNCTION, AND 
REJECTION EPISODES 
Several studies have compared prophylactic 
OKT3 following liver transplantation to standard 
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cyclosporine immunotherapy. Millis et al (10), pre-
sented the results of 52 patients randomized to 
either cyclosporine, azathioprine, and steroids (27 
patients), or to azathioprine, steroids, and OKT3, 
foHowed by conversion to cyclosporine at 14 days 
(25 patients). The incidence of rejection within the 
two weeks following transplantation was signifi-
cantly lower in the prophylactic group (41%) than in 
the control cyclosporine-treated group (72%. P < 
0.02). In addition. rejection occurred earlier in the 
control group (9.5 days vs 12.2 days, OKT3-treated 
group). Early renal function was better preserved in 
the prophylactic OKT3-1reated group as determined 
by serum creatinine (1.14 mgldl vs 1.45 mgldl for the 
control group). However, patient and graft survival 
was not significantly better, with the overall six-
month survival for the control group being 86% vs 
75% for the OKT3 prophylactic group. 
McDiarmid et aI (11) reported the results of the 
long-term follow-up of the patients reported by 
Millis et aI (10). In a larger series of 85 liver 
transplant recipients, 46 patients were randomized 
to receive prophylactic OKT3, while 39 patients 
were randomized to standard cyclosporine immu-
nosuppression. Patients dying during the first post-
transplant week were excluded from analysis. 
Long-term follow-up, with a mean survival of two 
years in both groups, showed a 69% survival in the 
OKT3 prophylactic group and an 84% survival with 
the standard cyclosporine immunosuppressive reg-
imen. Graft survival greater than 90 days was 61% 
in the OKT3 group and 74% in the control group. 
The incidence of rejection after 30 days was not 
different between the two groups. Renal function 
was not different between the two groups at 6, 12, 
or 24 months. Eight patients in the prophylactic 
group required a second course of OKT3. Reuse of 
OKTI was successful in reversing rejection only in 
five patients, primarily due to the presence of 
anti-OKT3 antibodies. They conclude from this 
study that no long-term benefits of OKT3 prophy-
laxis could be demonstrated with regards to graft or 
patient survival. incidence of. rejection after 30 
days, or renal function. 
Muhlbacher et aI (12), studied 88 consecutive 
patients following liver transplantation. Following 
transplant, 58 patients received cyclosporine and 
steroid, while 30 received prophylactic OKT3, ste-
roids, and azathioprine. Cyclosporine was substi-
tuted for OKT3 on day 10 posttransplantation. In 
this study, the overall one-year patient survival was 
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control group. Again, the incidence of rejection was 
statistically significantly reduced in the OKT3 pro-
phylactic group (56% vs 80%, control group, P = 
0.03). Renal function also was better preserved with 
a mean serum creatinine of 1.3 ± 1.0 mg/dl in the 
control cyclosporine-treated group while the pro-
phylactic group had a mean serum creatinine of 0.7 
:±: 0.4 mgldl (P < 0.05). 
Cosimi and coworkers (13) studied 79 patients 
randomized into a cyclosporine control group con-
sisting of triple drug immunosuppression with cy-
closporine. steroids, and azathioprine (42 patients), 
and 37 patients treated with prophylactic OKT3, 
azathioprine, and steroids followed by conversion 
to cyclosporine at 14 days. The incidence of rejec-
tion during the first two weeks was 42% in the 
prophylactic group versus 70% in the control group 
(P < 0.02). Renal function was reportedly better in 
the OKT3 group. The 14-month patient survival 
was 87% in the OKT3 group and 76% in the control 
group. 
INFECTIONS 
There are potential pitfalls of OKT3 use. The. 
major problem is the potentiation of infectious 
complications brought about by the. use of OKTI4: 
OKT3 is associated with an increase in the incj.;; 
dence of viral infections. Singh et al (14) examinedi 
the incidence of cytomegalovirus (CMV) and o~ 
herpes virus infections in liver transplant ,. 
and the effect of OKT3, given to treat rej4I:Ction,.om 
the severity of the viral disease. pymlptclma~ 
Jterpes simplex virus was increased from 3 
53% (P = 0.05) in patients receiving OKT3. 
inated CMV occurred more frequently with. 
use (P < 0.04). These findings were even . 
impressive in pediatric liver recipients. B01iV1D111l 
al (15) found that primary invasive CMV waa ......... 
fold higher in OKTI-treated patients than 
dren not receiving OKT3 (58% vs 19%, P < 
Adenovirus infections, not· commonly 
adults, was seen in 14% of pediatric patients 
ing OKT3, as compared to 2% in those not 
OKT3. Muhlbacher et al (12) could not deall~ 
an increased incidence of viral infections in 
receiving prophylactic OKT3, although all 
patients that died of severe viral iIlm:sse:.J 
received OKT3. In contrast, Millis et at 
cluded that there was not a significant 
incidence of infectious complications. 
rt the adult/pediatric composition ot' the patient 
JOpulations studied. 
DISCUSSION 
The purpose of this review is to summarize some 
)( the available information regarding the prophy-
actic use of OKT3 following liver transplantation 
LRd to clarify the situation(s) in which this agent 
night be utilized. The main questions are: (1) 
.vhether prophylactic use versus selective use of 
)KTI in liver transplant patients can effect patient 
lnd graft survival, (2) whether a decrease in the 
ncidence of rejection during the first few weeks 
'ollowing transplantation is helpful in the overall 
,nanagement of these patients, (3) if the avoidance 
Jf cyclosporine during the early posttransplant pe-
riod results in an improvement in renal function, (4)-
If the nonselective use of OKT3 adversely affects 
the requirement for subsequent use of OKT3, and 
(5) whether the infectious complications outweigh 
the potential benefits of prophylactic use of OKT3. 
It may not be possible to answer all of these 
questions at this time; however, several general 
conclusions can be made. 
Prophylactic OKT3 has not been determined in 
any study to lead to an increased patient or graft 
survival. In a study by Fung et al (7), the more 
selective use of OKT3 early in the posttransplant 
period, in patients with renal dysfunction or early 
liver allograft dysfunction, was associated with a 
"normalization" in patient and graft survival. 
These figures were not better than those obtained 
with more "blue ribbon" patients, but were better 
than those previously reported in patients with such 
complications. 
The avoidance of cyclosporine during the imme-
diate posttransplant period appears to benefit early 
renal function following liver transplantation. It is 
also clear that the long-term nephrotoxicity of 
OKT3 is not inftuenced by these early posttrans-
plant events. Nevertheless, prevention of early re-
nal dysfunction allows the transplant leam to man-
age ftuid and electrolytes more easily and decrease 
the morbidity associated with the need for hemodi-
alysis. Selective administration of OKT3 to patients 
manifesting the hepatorenal syndrome prior to 
transplantation or to those who develop early post-
operative oliguria may reduce the early need for 
hemodialysis, although this question has not been 
prospectively studied in a randomized fashion. 
Dlr'lliv, Dis,as,s and Sci,nc,s. Vol. J6. No. 10 (October 1991) 
The rate ot' sensitizauou to the munne ,uad IUlu-
type components of OKT3 occurs at a rate to 
20-40% (16). Va.rious strategies have been devel-
oped10 overcome such a sensitization state, such as 
increasing the dose of OKT3 and carefully monitor-
ing T-cell subpopulations. The success of reuse of 
OKT3 is less than that for primary use, both when 
OKT3 is used for prophylaxis or for treatment (5, 
18). This strategy may be associated with an even 
higher incidence of infectious complications (19). 
Perhaps with the availability of "humanized" 
OKT3, the difficulty with sensitization precluding 
successful reuse of OKT3 may be avoided. 
It is clear that OKT3 can potentiate the susceptibil-
ity to viral infections when used to treat acute al-
lograft rejections. It is not clear that prophylactic use 
of OKT3 does the same. In a kidney transplant study 
using prophylactic OKTI, the incidence of viral infec-
tions was higher in the prophylactic group when 
compared to azathioprine and steroids (18); however, 
the length of 0 KTI prophylaxis and the nature of the 
control groups were different than what is the current 
standard for liver transplantation. Generally, the de-
velopment of viral infections can be managed by 
specific antiviral therapy; however, the ominous de-
velopment of lymphoproliferative disease (LPD), is 
associated with increased mortality. In several re-
ports, the development of EBV -associated LPD was 
associated with the use ofOKT3 (20,21). Whether the 
addition of prophylactic antiviral therapy can de-
crease the incidence and severity of viral infections, in 
the context ofOKTI immunoprophylaxis, is currently 
being evaluated (22). 
It can be argued that the tradeoff of sensitization 
and susceptibility to infections with the ease in the 
management of liver transplant patients during the 
first few weeks after liver transplantation is justified. 
However, without an appreciable impact on long-
tenn graft or patient survival, cost analysis becomes a 
paramount factor in detennining the usefulness of 
prophylactic OKT3. If one were to take 100 liver 
transplant patients and treat them with prophylactic 
OKT3 for 14 days, the drug costs alone will be 
$840,000, assuming It cost to the patient of $60015 mg. 
Once the costs of drug administration and premedica-
tion charges are added, this cost will rise to 
$1,000,000. If monitoring of drug levels of OKT3 
and/or detennination of T -ceO subpopulations are 
added, these costs could add an additional $1000 per 
patient (assuming that only two detenninations were 
made during the course of prophylaxis). If one as-
sumes that 20% of these patients will require a second 
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course of OKT3 , then the additional drug charges will 
be $200,000, and the monitoring charges will be 
$40,000. The total charges would be expected to 
approach $1 ,500,000. On the other hand, selective use 
of OKTI for those with early renal dysfunction (20%) 
or those requiring OKT3 for steroid-resistant rejec-
tion (25%) would decrease the total charges for OKT3 
and monitoring to about one third that of the prophy-
lactic group. The savings of $ t .000.000 alone would 
serve as justification for a more judicious use of 
OKTI. 
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